• Calhoun Vision (Pasadena, California), developer of ocular technology designed to allow cataract surgeons to adjust the power of a lens after implantation in the eye, reported the enrollment of the 300th patient in the phase III clinical study of its Light Adjustable Lens (LAL). The study, which is being conducted at 18 centers across the country, will include a total of 600 patients, with 400 implanted with the LAL and 200 implanted with a monofocal control lens of the surgeon's choosing. Unlike traditional intraocular lenses, which are made of non-adjustable material, the LAL technology is designed to allow surgeons for the first time to change and customize the power of the lens after it has been implanted in the eye. The LAL is implanted in the same way as with standard cataract surgery, but because it is adjusted after implantation, the lens' performance is not affected by variables such as wound healing and changes in lens position. The patient returns for one or two follow-up visits, during which the surgeon evaluates his or her vision and performs an adjustment to customize the lens to the individual patient. This is accomplished by exposing the lens to UV light from a special light delivery device, which changes the shape and power of the lens. Once the desired visual target is achieved, the surgeon locks in the lens with a final light treatment to prevent any further power change.